Processa Pharmaceuticals, Inc. PCSA
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
-48.58
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$13.6M | — | — | $5.6M |
| 2024 | — | -$11.9M | — | -$11.2M | $1.7M |
| 2023 | — | -$11.1M | — | -$8.1M | $5.0M |
| 2022 | $0 | -$27.4M | — | — | $7.5M |
| 2021 | $0 | -$11.4M | — | — | $25.5M |
| 2020 | — | -$14.4M | — | — | $22.9M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -48.58 (distress)
- Working capital / assets 0.44
- Retained earnings / assets -12.898
- EBIT / assets -1.79
- Equity / liabilities 2.494
Source: SEC EDGAR filings · CIK 0001533743 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.